SHARE

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is on a run after it gained appreciation from two small-cap research companies. The stock jumped up by nearly 29% to $0.147 during the yesterday trade, where an average volume of 1.81 million shares changed hands. Firstly, the company received coverage from TickerResearch, which said that the company’s Cell-in-a-Box technology has a great potential to a breakthrough in the treatment of pancreatic cancer.

Cell-in-a-box

The research firm said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) holds exclusive rights to develop therapies to treat solid cancerous tumors through its Cell-in-a-box technology in combination with drug ifosfamide in low combinations. The firm added that Pharmacyte Biotech Inc (OTCMKTS:PMCB) already has earned Orphan Drug Status for its technology that puts it ahead in the race of developing treatment for advanced pancreatic cancer.

The company is expected to clinical trials to test the efficacy and effectiveness of its solution against industry standard treatment, Gemcitabine. If the company can report positive results from trial, then it will be its turning point. The research firm stated that Pharmacyte Biotech Inc (OTCMKTS:PMCB) could be the next biotech winner in the market.

More hidden potential

Similarly, another research firm, Goldman Small Cap Research too take a positive view on the stock. The firm’s analyst Rob Goldman said that the company is positioned attractively, where it has a caliber to develop a therapy for the treatment of multiple forms of diabetes and cancer. The research firm reiterated that the Orphan Drug status will boost the company’s development efforts and could make it as a chief player in the treatment of pancreatic cancer.

The firm suggested that the potential of the company has been overlooked, and there is a lot more value in the stock than estimated. The firm also highlighted the possibility that the company’s technology has the chances to cure a number of diseases including diabetes and other forms of cancer.

LEAVE A REPLY